Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jun;39(6):1287–1291. doi: 10.1128/aac.39.6.1287

Antiviral susceptibility testing with a cell line which expresses beta-galactosidase after infection with herpes simplex virus.

P Tebas 1, E C Stabell 1, P D Olivo 1
PMCID: PMC162728  PMID: 7574517

Abstract

Despite increasing concern about drug-resistant herpes simplex virus (HSV), antiviral susceptibility testing is not routinely performed by most clinical virology laboratories. This omission is in large part because the most widely accepted method, the plaque reduction assay (PRA), is cumbersome to perform and results are rarely available in time to influence treatment. We report here the development of a sensitivity test for HSV which utilizes a cell line (VeroICP6LacZ#7) that expresses beta-galactosidase activity after infection with HSV such that infected cells can be detected by histochemical staining. We designed an assay in which 10-fold dilutions of virus stocks with undetermined titers were inoculated onto VeroICP6LacZ#7 cells in a 24-well tissue culture dish. Forty-eight hours after infection, the cell monolayers were histochemically stained. Plaques appear blue against a clear background and are thus easily visualized at 48 h. As with the standard PRA, the 50% inhibitory concentration (IC50) was reported as the concentration of an antiviral drug that reduces the number of plaques by 50%. Evaluation of 10 well-characterized laboratory strains and 12 clinical HSV isolates showed that the IC50 determined by this method correlated in all instances with the IC50 determined by the PRA. This method is easy to use and eliminates the need to determine the titer of the virus, and results are available within 48 h of the detection of the virus. VeroICP6Lac#7 cells are a useful tool for performing HSV antiviral susceptibility testing and could be used in a number of different formats to facilitate the identification of drug-resistant isolates of HSV.

Full Text

The Full Text of this article is available as a PDF (617.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agut H., Aubin J. T., Ingrand D., Blanc S., Clayton A. L., Chantler S. M., Huraux J. M. Simplified test for detecting the resistance of herpes simplex virus to acyclovir. J Med Virol. 1990 Jul;31(3):209–214. doi: 10.1002/jmv.1890310307. [DOI] [PubMed] [Google Scholar]
  2. André P. M., Narbonne C. H., Donnio P. Y., Ruffault A., Fauconnier B. Evaluation of herpes simplex virus susceptibility to acyclovir using an enzyme-linked immunosorbent assay. Ann Inst Pasteur Virol. 1988 Apr-Jun;139(2):185–195. doi: 10.1016/s0769-2617(88)80016-9. [DOI] [PubMed] [Google Scholar]
  3. Balfour H. H., Jr Resistance of herpes simplex to acyclovir. Ann Intern Med. 1983 Mar;98(3):404–406. doi: 10.7326/0003-4819-98-3-404. [DOI] [PubMed] [Google Scholar]
  4. Coen D. M., Kosz-Vnenchak M., Jacobson J. G., Leib D. A., Bogard C. L., Schaffer P. A., Tyler K. L., Knipe D. M. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4736–4740. doi: 10.1073/pnas.86.12.4736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Darby G., Field H. J., Salisbury S. A. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature. 1981 Jan 1;289(5793):81–83. doi: 10.1038/289081a0. [DOI] [PubMed] [Google Scholar]
  6. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ellis M. N., Keller P. M., Fyfe J. A., Martin J. L., Rooney J. F., Straus S. E., Lehrman S. N., Barry D. W. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother. 1987 Jul;31(7):1117–1125. doi: 10.1128/aac.31.7.1117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Englund J. A., Zimmerman M. E., Swierkosz E. M., Goodman J. L., Scholl D. R., Balfour H. H., Jr Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med. 1990 Mar 15;112(6):416–422. doi: 10.7326/0003-4819-76-3-112-6-416. [DOI] [PubMed] [Google Scholar]
  9. Erlich K. S., Mills J., Chatis P., Mertz G. J., Busch D. F., Follansbee S. E., Grant R. M., Crumpacker C. S. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 2;320(5):293–296. doi: 10.1056/NEJM198902023200506. [DOI] [PubMed] [Google Scholar]
  10. Field A. K., Biron K. K. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev. 1994 Jan;7(1):1–13. doi: 10.1128/cmr.7.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gray J. J., Wreghitt T. G., Baglin T. P. Susceptibility to acyclovir of herpes simplex virus: emergence of resistance in patients with lymphoid and myeloid neoplasia. J Infect. 1989 Jul;19(1):31–40. doi: 10.1016/s0163-4453(89)94798-1. [DOI] [PubMed] [Google Scholar]
  12. Harmenberg J., Sundqvist V. A., Gadler H., Levén B., Brännström G., Wahren B. Comparative methods for detection of thymidine kinase-deficient herpes simplex virus type 1 strains. Antimicrob Agents Chemother. 1986 Oct;30(4):570–573. doi: 10.1128/aac.30.4.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Helgstrand E., Eriksson B., Johansson N. G., Lannerö B., Larsson A., Misiorny A., Norén J. O., Sjöberg B., Stenberg K., Stening G. Trisodium phosphonoformate, a new antiviral compound. Science. 1978 Sep 1;201(4358):819–821. doi: 10.1126/science.210500. [DOI] [PubMed] [Google Scholar]
  14. Jofre J. T., Schaffer P. A., Parris D. S. Genetics of resistance to phosphonoacetic acid in strain KOS of herpes simplex virus type 1. J Virol. 1977 Sep;23(3):833–836. doi: 10.1128/jvi.23.3.833-836.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kruppenbacher J. P., Kläss R., Eggers H. J. A rapid and reliable assay for testing acyclovir sensitivity of clinical herpes simplex virus isolates independent of virus dose and reading time. Antiviral Res. 1994 Jan;23(1):11–22. doi: 10.1016/0166-3542(94)90029-9. [DOI] [PubMed] [Google Scholar]
  16. McLaren C., Ellis M. N., Hunter G. A. A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents. Antiviral Res. 1983 Nov;3(4):223–234. doi: 10.1016/0166-3542(83)90001-3. [DOI] [PubMed] [Google Scholar]
  17. Nugier F., Colin J. N., Aymard M., Langlois M. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol. 1992 Jan;36(1):1–12. doi: 10.1002/jmv.1890360102. [DOI] [PubMed] [Google Scholar]
  18. Safrin S., Crumpacker C., Chatis P., Davis R., Hafner R., Rush J., Kessler H. A., Landry B., Mills J. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1991 Aug 22;325(8):551–555. doi: 10.1056/NEJM199108223250805. [DOI] [PubMed] [Google Scholar]
  19. Safrin S., Elbeik T., Mills J. A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates. J Infect Dis. 1994 Apr;169(4):879–882. doi: 10.1093/infdis/169.4.879. [DOI] [PubMed] [Google Scholar]
  20. Safrin S., Kemmerly S., Plotkin B., Smith T., Weissbach N., De Veranez D., Phan L. D., Cohn D. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis. 1994 Jan;169(1):193–196. doi: 10.1093/infdis/169.1.193. [DOI] [PubMed] [Google Scholar]
  21. Sibrack C. D., Gutman L. T., Wilfert C. M., McLaren C., St Clair M. H., Keller P. M., Barry D. W. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis. 1982 Nov;146(5):673–682. doi: 10.1093/infdis/146.5.673. [DOI] [PubMed] [Google Scholar]
  22. Stabell E. C., Olivo P. D. Isolation of a cell line for rapid and sensitive histochemical assay for the detection of herpes simplex virus. J Virol Methods. 1992 Aug;38(2):195–204. doi: 10.1016/0166-0934(92)90110-y. [DOI] [PubMed] [Google Scholar]
  23. Swierkosz E. M., Scholl D. R., Brown J. L., Jollick J. D., Gleaves C. A. Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus. Antimicrob Agents Chemother. 1987 Oct;31(10):1465–1469. doi: 10.1128/aac.31.10.1465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sze P., Herman R. C. The herpes simplex virus type 1 ICP6 gene is regulated by a 'leaky' early promoter. Virus Res. 1992 Nov;26(2):141–152. doi: 10.1016/0168-1702(92)90153-z. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES